ECSP14030942A - Anticuerpos de anti-transglutaminasa 2 - Google Patents

Anticuerpos de anti-transglutaminasa 2

Info

Publication number
ECSP14030942A
ECSP14030942A ECIEPI201430942A ECPI201430942A ECSP14030942A EC SP14030942 A ECSP14030942 A EC SP14030942A EC IEPI201430942 A ECIEPI201430942 A EC IEPI201430942A EC PI201430942 A ECPI201430942 A EC PI201430942A EC SP14030942 A ECSP14030942 A EC SP14030942A
Authority
EC
Ecuador
Prior art keywords
antibodies
transglutaminase
core
provides
scarring
Prior art date
Application number
ECIEPI201430942A
Other languages
English (en)
Spanish (es)
Inventor
Alex Brown
David Matthews
Phil Watson
Tim Johnson
Original Assignee
Medical Research Council Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46546551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14030942(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medical Research Council Tech filed Critical Medical Research Council Tech
Publication of ECSP14030942A publication Critical patent/ECSP14030942A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
ECIEPI201430942A 2012-05-24 2014-12-12 Anticuerpos de anti-transglutaminasa 2 ECSP14030942A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1209096.5A GB201209096D0 (en) 2012-05-24 2012-05-24 Compounds

Publications (1)

Publication Number Publication Date
ECSP14030942A true ECSP14030942A (es) 2015-09-30

Family

ID=46546551

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201430942A ECSP14030942A (es) 2012-05-24 2014-12-12 Anticuerpos de anti-transglutaminasa 2

Country Status (39)

Country Link
US (3) US10005846B2 (enExample)
EP (2) EP2855530B1 (enExample)
JP (2) JP6411998B2 (enExample)
KR (1) KR102091223B1 (enExample)
CN (1) CN104321346B (enExample)
AU (1) AU2013265025B2 (enExample)
BR (1) BR112014029089B1 (enExample)
CA (1) CA2874488C (enExample)
CL (1) CL2014003125A1 (enExample)
CO (1) CO7151528A2 (enExample)
CY (2) CY1121932T1 (enExample)
DK (2) DK2855530T3 (enExample)
EA (1) EA036810B1 (enExample)
EC (1) ECSP14030942A (enExample)
ES (2) ES2835383T3 (enExample)
GB (1) GB201209096D0 (enExample)
HR (2) HRP20191293T1 (enExample)
HU (2) HUE052490T2 (enExample)
IL (1) IL235369B (enExample)
IN (1) IN2014MN02231A (enExample)
LT (2) LT2855530T (enExample)
MA (1) MA37670B1 (enExample)
ME (1) ME03393B (enExample)
MX (1) MX367517B (enExample)
MY (1) MY185966A (enExample)
NZ (1) NZ701424A (enExample)
PE (1) PE20150346A1 (enExample)
PH (1) PH12014502582A1 (enExample)
PL (2) PL3521315T3 (enExample)
PT (2) PT3521315T (enExample)
RS (2) RS59135B1 (enExample)
SG (1) SG11201407053YA (enExample)
SI (2) SI2855530T1 (enExample)
SM (2) SMT202100014T1 (enExample)
TN (1) TN2014000458A1 (enExample)
TR (1) TR201906781T4 (enExample)
UA (1) UA117657C2 (enExample)
WO (1) WO2013175229A1 (enExample)
ZA (1) ZA201408213B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110055235A (zh) * 2019-05-14 2019-07-26 深圳市亚辉龙生物科技股份有限公司 用于转谷氨酰胺酶抗体检测的抗原及其制备方法、试剂盒及检测方法
FR3117599B1 (fr) * 2020-12-16 2024-11-29 Oreal Méthode de pronostic et/ou de diagnostic d’un état pelliculaire du cuir chevelu
GB202115121D0 (en) 2021-10-21 2021-12-08 Ucb Biopharma Sprl Formulations
GB202115127D0 (en) 2021-10-21 2021-12-08 Ucb Biopharma Sprl Formulations
CA3238305A1 (en) 2021-11-18 2023-05-25 Timothy Scott JOHNSON Method for the treatment of progressive chronic interstitial lung disease
GB202116665D0 (en) 2021-11-18 2022-01-05 UCB Biopharma SRL Method for the treatment of a scleroderma disease
GB202118010D0 (en) 2021-12-13 2022-01-26 UCB Biopharma SRL Method for detecting and/or quantifying crosslinks formed by transglutaminases
CN116515786B (zh) * 2023-04-26 2024-05-28 广东医科大学 一种人tgm3乙酰化多肽、抗原、抗体及其制备方法和应用
WO2025153465A1 (en) * 2024-01-15 2025-07-24 UCB Biopharma SRL Method for the treatment of fibrotic-related disorder associated to ibd
WO2026162317A1 (en) 2025-01-28 2026-08-06 Chiesi Farmaceutici S.P.A. Treatment of progressive chronic interstitial lung disease with an anti-tg2 antibody

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912120A (en) 1986-03-14 1990-03-27 Syntex (U.S.A.) Inc. 3,5-substituted 4,5-dihydroisoxazoles as transglutaminase inhibitors
AU1268192A (en) 1991-01-04 1992-08-17 Board Of Regents, The University Of Texas System Cloning and expression of tissue transglutaminases
WO1998004245A1 (en) 1996-07-25 1998-02-05 The Victoria University Of Manchester Use of transglutaminase modulators to promote wound healing
GB0103024D0 (en) * 2001-02-07 2001-03-21 Rsr Ltd Assay for Autoantibodies to tissue transglutaminase
US20060211624A1 (en) 2003-02-02 2006-09-21 Goverment of the US, as Represented by Methods and compositions for the treatment of parkinson's disease and other alpha-synucleinopathies
GB0314262D0 (en) 2003-06-19 2003-07-23 Univ Nottingham Trent Novel compounds and methods of using the same
WO2006100679A2 (en) * 2005-03-22 2006-09-28 Quark Pharmaceuticals, Inc. Recombinant antibodies against human type ii transglutaminase and uses thereof
US8299040B2 (en) 2006-10-18 2012-10-30 Board Of Regents, The University Of Texas System Methods for treating cancer targeting transglutaminase
KR101746861B1 (ko) * 2008-04-24 2017-06-14 가부시키가이샤 진 테크노 사이언스 세포 외 기질 단백질의 아미노산 서열 ｒｇｄ에 특이적인 인간화된 항체 및 그의 용도
NZ595731A (en) 2009-03-19 2013-09-27 Univ Queensland Targets for growth factor signalling and methods of therapy
HU0900195D0 (en) * 2009-04-01 2009-06-29 Debreceni Egyetem Diagnosis and treatment of gluten-induced autoimmune diseases
HU0900199D0 (en) * 2009-04-01 2009-06-29 Debreceni Egyetem Diagnosis of gluten-induced autoimmune diseases
WO2011151395A2 (en) 2010-06-02 2011-12-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Transglutaminase 2 inhibitors for use in the prevention or treatment of rapidly progressive glomerulonephritis
GB2490655A (en) 2011-04-28 2012-11-14 Univ Aston Modulators of tissue transglutaminase

Also Published As

Publication number Publication date
ZA201408213B (en) 2020-02-26
AU2013265025A1 (en) 2014-12-04
SMT202100014T1 (it) 2021-03-15
HK1203974A1 (en) 2015-11-06
RS59135B1 (sr) 2019-09-30
JP2015519897A (ja) 2015-07-16
SI3521315T1 (sl) 2020-12-31
BR112014029089B1 (pt) 2023-04-25
US10005846B2 (en) 2018-06-26
HUE052490T2 (hu) 2021-04-28
SMT201900407T1 (it) 2019-09-09
SI2855530T1 (sl) 2019-08-30
JP6411998B2 (ja) 2018-10-24
MA37670A1 (fr) 2016-05-31
CY1121932T1 (el) 2020-10-14
CN104321346B (zh) 2018-12-07
PL3521315T3 (pl) 2021-08-23
UA117657C2 (uk) 2018-09-10
MX367517B (es) 2019-08-26
PT2855530T (pt) 2019-07-08
EA036810B1 (ru) 2020-12-23
PE20150346A1 (es) 2015-03-05
CN104321346A (zh) 2015-01-28
EP3521315B1 (en) 2020-10-14
EP2855530B1 (en) 2019-05-01
CL2014003125A1 (es) 2015-08-21
DK3521315T3 (da) 2020-11-09
CY1123926T1 (el) 2022-05-27
KR20150013340A (ko) 2015-02-04
ME03393B (me) 2020-01-20
ES2835383T3 (es) 2021-06-22
EP2855530A1 (en) 2015-04-08
BR112014029089A2 (pt) 2019-06-25
US11718686B2 (en) 2023-08-08
IL235369B (en) 2019-05-30
RS61286B1 (sr) 2021-02-26
IN2014MN02231A (enExample) 2015-07-24
KR102091223B1 (ko) 2020-03-20
PH12014502582B1 (en) 2015-01-21
CA2874488C (en) 2021-09-07
ES2728856T3 (es) 2019-10-29
US10961319B2 (en) 2021-03-30
TN2014000458A1 (en) 2016-03-30
LT2855530T (lt) 2019-07-25
PL2855530T3 (pl) 2019-10-31
PH12014502582A1 (en) 2015-01-21
US20210101999A1 (en) 2021-04-08
MY185966A (en) 2021-06-14
PT3521315T (pt) 2020-10-29
US20150218289A1 (en) 2015-08-06
LT3521315T (lt) 2020-12-28
GB201209096D0 (en) 2012-07-04
MA37670B1 (fr) 2019-12-31
IL235369A0 (en) 2014-12-31
WO2013175229A1 (en) 2013-11-28
SG11201407053YA (en) 2014-12-30
NZ701424A (en) 2016-08-26
TR201906781T4 (tr) 2019-05-21
CO7151528A2 (es) 2014-12-29
US20180355060A1 (en) 2018-12-13
DK2855530T3 (da) 2019-06-24
HUE045539T2 (hu) 2019-12-30
JP2018166510A (ja) 2018-11-01
EA201492162A1 (ru) 2015-03-31
EP3521315A1 (en) 2019-08-07
HRP20202059T1 (hr) 2021-02-19
CA2874488A1 (en) 2013-11-28
MX2014014264A (es) 2015-05-15
HRP20191293T1 (hr) 2019-10-18
AU2013265025B2 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
CO7151528A2 (es) Anticuerpos de anti-transglutaminasa 2
JOP20200192A1 (ar) أجسام مضادة لـ tigit
CL2021002637A1 (es) Anticuerpos y fragmentos de los mismos que se unen al receptor cannabinoide 1 (cb1) humano y métodos para antagonizar cb1 (divisional de la solicitud no. 201602433)
MX2017006167A (es) Compuestos que interactúan con glicanos y métodos de uso.
CO2018000809A2 (es) Anticuerpos para cd40
MX2018005061A (es) Compuestos de interacción con glicanos y métodos de uso.
CO2017013356A2 (es) Anticuerpos de factor xi
MX393066B (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
MX2018002043A (es) ANTICUERPOS ANTI-BCMA, MOLí‰CULAS DE UNIí“N A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS.
MX2017001011A (es) Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
NZ727024A (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
MX2017014188A (es) Anticuerpos anti-ox40 y metodos para su uso.
MX391107B (es) Moléculas que enlazan cd3 capaces de enlazar a cd3 humano y no humano.
EA201791050A1 (ru) Конъюгаты антител и лекарственных средств
MX358321B (es) Anticuerpos anti-ceacam5 y usos de los mismos.
ECSP12012309A (es) Anticuerpos hacia gdf8 humano
MX376808B (es) Anticuerpos anti-b7-h5 y sus usos.
EA201590412A1 (ru) Композиции антител и их применения
ECSP12012202A (es) Anticuerpos il-25 humanizados
MX2017012397A (es) Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache).
MX2018006613A (es) Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.
CO2018004569A2 (es) Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano
MX2020009130A (es) Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos.
CR20190086A (es) Anticuerpo o un fragmento de union a antígeno del mismo, capaz de unirsea un receptor humano de interleucina-6